.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,602,130

« Back to Dashboard

Details for Patent: 5,602,130

Title: Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
Abstract:Retinoid-like activity is exhibited by compounds of the formula ##STR1## where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4; and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH.sub.2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR.sub.1 or a ketal derivative where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt thereof.
Inventor(s): Chandraratna; Roshantha A. (Mission Viejo, CA)
Assignee: Allergan (N/A)
Filing Date:Oct 14, 1994
Application Number:08/323,174
Claims:1. A process of treating a mammal afflicted with a condition or disease which is susceptible to treatment by a therapeutic agent having retinoid-like activity, the process comprising administering to said mammal an effective dose of a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound having the formula ##STR11## where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4; and B is H, --COOH or a pharmaceutically acceptable salt thereof, or an ester thereof with a saturated aliphatic alcohol of ten or fewer carbon atoms, or with a cyclic or saturated aliphatic cyclic alcohol of 5 to 10 carbon atoms, or with phenol or with a lower alkylphenol, or an amide or a mono or di-substituted amide thereof, the subtituents on the amide being selected from a group consisting of saturated aliphatic radicals of ten or fewer carbon atoms, cyclic or saturated aliphatic cyclic radicals of 5 to 10 carbon atoms, and phenyl or lower alkylphenyl radicals, or B is CH.sub.2 OH or an ester derivative thereof derived from a saturated aliphatic acid of ten or fewer carbon atoms, or from a cyclic or saturated aliphatic cyclic acid of 5 to 10 carbon atoms, or from benzoic acid, or an ether derivative thereof derived from a saturated aliphatic radical of ten or fewer carbon atoms, or from a cyclic or saturated aliphatic cyclic radical of 5 to 10 carbon atoms, or from phenyl or lower alkylphenyl radical, or B is --CHO or a lower alkyl acetal derivative thereof, or an acetal derivative thereof formed with a lower alkyl diol, or B is --COR.sub.1 or a lower alkyl ketal derivative thereof, or a ketal derivative thereof formed with a lower alkyl diol, where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt of the compound defined in said formula.

2. The process of claim 1 where in the formula of the compound X is S, R is hydrogen, A is pyridyl, thienyl or furyl, and n is 0 or 1.

3. The process of claim 2 where in the formula of the compound A is pyridyl and B is COOH or a pharmaceutically acceptable salt, lower alkyl ester or mono or di-lower alkyl amide thereof.

4. The process of claim 3 where the compound is ethyl 6-[2-4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate, 6-[2-4,4-dimethylthiochroman-6yl)ethynyl]nicotinic acid or a pharmaceutically acceptable salt of said compounds.

5. The process of claim 2 where in the formula of the compound A is thienyl.

6. The process of claim 5 where the compound is ethyl 5-[2-(4,4-dimethyl thiochroman-6-yl)ethynyl]thienyl-2-carboxylate or a pharmaceutically acceptable salt thereof.

7. The process of claim 1 where in the formula of the compound X is S, R is lower alkyl, A is pyridyl, thienyl or furyl, and n is 0 or 1.

8. The process of claim 7 where the compound is ethyl 6-[2-(4,4,7-trimethylthiochroman-6-yl)ethynyl]nicotinate, 6-[2-(4,4,7-trimethylthiochroman-6-yl)ethynyl]nicotinic acid or a pharmaceutically acceptable salt thereof.

9. The process of claim 1 where in the formula of the compound X is O, R is hydrogen, A is pyridyl, thienyl or furyl, and n is 0 or 1.

10. The process of claim 9 where in the formula of the compound A is pyridyl and B is COOH or a pharmaceutically acceptable salt, lower alkyl ester or mono or di-lower alkyl amide thereof.

11. The process of claim 10 where the compound is ethyl 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinate, 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinic acid, or a pharmaceutically acceptable salt thereof.

12. The process of claim 1 where in the formula of the compounds X is NR', R is hydrogen, A is pyridyl, thienyl or furyl, and n is 0 or 1.

13. The process of claim 12 where in the formula of the compound A is pyridyl and B is COOH or a pharmaceutically acceptable salt, lower alkyl ester or mono or di-lower alkyl amide thereof.

14. The process of claim 13 where the compound is ethyl 6-[2-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl]nicotinate, 6-[2-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl]nicotinic acid, or a pharmaceutically acceptable salt thereof.

15. A process of treating a mammal afflicted with a condition or disease selected from actinic keratoses, arsenic keratoses, inflammatory acne, non-inflammatory acne, psoriasis, ichthyoses, keratinization, hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, glucocorticoid damage (steroid atrophy), topical microbial infection, skin pigmentation, photo damage to the skin, premalignant and malignant hyperproliferative diseases, cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynxy, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias, papillomas of the mucous membranes, Kaposi's sarcoma, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, dyslipidemias, post-angioplasty restenosis, diseases associated with Human papilloma virus (HPV), inflammatory diseases, pulmonary fibrosis, ileitis, colitis, Krohn's disease, neurodegenerative diseases, Parkinson's disease and stroke, improper pituitary function, modulation of apoptosis, diseases of the immune system, modulation of organ transplant rejection and facilitation of wound healing, and as agent to increase the level of circulating tissue plasminogen activator (TPA) and for restoring hair growth,

the process comprising administering to said mammal an effective dose of a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound having the formula ##STR12## where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4 and B is H, --COOH or a pharmaceutically acceptable salt thereof, or an ester thereof with a saturated aliphatic alcohol of ten or fewer carbon atoms, or with a cyclic or saturated aliphatic cyclic alcohol of 5 to 10 carbon atoms, or with phenol or with a lower alkylphenol, or an amide or a mono or di-substituted amide thereof, the subtituents on the amide being selected from a group consisting of saturated aliphatic radicals of ten or fewer carbon atoms, cyclic or saturated aliphatic cyclic radicals of 5 to 10 carbon atoms, and phenyl or lower alkylphenyl radicals, or B is CH.sub.2 OH or an ester derivative thereof derived from a saturated aliphatic acid of ten or fewer carbon atoms, or from a cyclic or saturated aliphatic cyclic acid of 5 to 10 carbon atoms, or from benzoic acid, or an ether derivative thereof derived from a saturated aliphatic radical of ten or fewer carbon atoms, or from a cyclic or saturated aliphatic cyclic radical of 5 to 10 carbon atoms, or from phenyl or lower alkylphenyl radical, or B is --CHO or a lower alkyl acetal derivative thereof, or an acetal derivative thereof formed with a lower alkyl diol, or B is --COR.sub.1 or a lower alkyl ketal derivative thereof, or a ketal derivative thereof formed with a lower alkyl diol, where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt of the compound defined in said formula.

16. The process of claim 15 where in the formula of the compound X is S.

17. The process of claim 16 where in the formula of the compound A is pyridyl.

18. The process of claim 15 where in the formula of the compound X is O.

19. The process of claim 18 where in the formula of the compound X is pyridyl.

20. The process of claim 15 where in the formula of the compound X is NR' and R' is H.

21. The process of claim 20 where in the formula of the compound A is pyridyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc